Literature DB >> 32004468

Harnessing the Power of Proteolysis for Targeted Protein Inactivation.

Rati Verma1, Dane Mohl2, Raymond J Deshaies2.   

Abstract

Two decades into the twenty-first century, a confluence of breakthrough technologies wielded at the molecular level is presenting biologists with unique opportunities to unravel the complexities of the cellular world. CRISPR/Cas9 allows gene knock-outs, knock-ins, and single-base editing at chromosomal loci. RNA-based tools such as siRNA, antisense oligos, and morpholinos can be used to silence expression of specific genes. Meanwhile, protein knockdown tools that draw inspiration from natural regulatory mechanisms and facilitate elimination of native or degron-tagged proteins from cells are rapidly emerging. The acute and reversible reduction in protein levels enabled by these methods allows for precise determination of loss-of-function phenotypes free from secondary effects or compensatory adaptation that can confound nucleic-acid-based methods that involve slow depletion or permanent loss of a protein. In this Review, we summarize the ingenious ways biologists have exploited natural mechanisms for protein degradation to direct the elimination of specific proteins at will. This has led to advancements not only in basic research but also in the therapeutic space with the introduction of PROTACs into clinical trials for cancer patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32004468     DOI: 10.1016/j.molcel.2020.01.010

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  39 in total

1.  Dissenting degradation: Deubiquitinases in cell cycle and cancer.

Authors:  Thomas Bonacci; Michael J Emanuele
Journal:  Semin Cancer Biol       Date:  2020-03-20       Impact factor: 15.707

2.  Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.

Authors:  Rati Verma
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  A kinetic proofreading model for bispecific protein degraders.

Authors:  Derek W Bartlett; Adam M Gilbert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-22       Impact factor: 2.745

4.  Transfer of ubiquitin protein caught in the act.

Authors:  Raymond J Deshaies; Nathan W Pierce
Journal:  Nature       Date:  2020-02       Impact factor: 49.962

Review 5.  NEDD8 and ubiquitin ligation by cullin-RING E3 ligases.

Authors:  Kheewoong Baek; Daniel C Scott; Brenda A Schulman
Journal:  Curr Opin Struct Biol       Date:  2020-11-05       Impact factor: 6.809

6.  Target-induced clustering activates Trim-Away of pathogens and proteins.

Authors:  Jingwei Zeng; Ana Filipa Santos; Aamir S Mukadam; Mariana Osswald; David A Jacques; Claire F Dickson; Stephen H McLaughlin; Christopher M Johnson; Leo Kiss; Jakub Luptak; Nadine Renner; Marina Vaysburd; William A McEwan; Eurico Morais-de-Sá; Dean Clift; Leo C James
Journal:  Nat Struct Mol Biol       Date:  2021-02-25       Impact factor: 15.369

Review 7.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

Review 8.  Recent Advances in Single-Cell Profiling and Multispecific Therapeutics: Paving the Way for a New Era of Precision Medicine Targeting Cardiac Fibroblasts.

Authors:  Brandon Ason; Milena B Furtado; Sally Yu Shi; Xin Luo; Tracy M Yamawaki; Chi-Ming Li
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

9.  USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates.

Authors:  Thang Van Nguyen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-05       Impact factor: 11.205

10.  Expression and purification of functional recombinant CUL2•RBX1 from E. coli.

Authors:  Stephanie Diaz; Lihong Li; Kankan Wang; Xing Liu
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.